PUMA BIOTECHNOLOGY, INC. (PBYI)
D
Pipeline Grade
Financial Position (from SEC Filings)
$72.6M
Cash & Equivalents
$15.4M
Quarterly Burn Rate
$372M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06095505 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | PHASE2 | Recruiting | 80 |
| NCT04502602 | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer | PHASE1 | Active Not Recruiting | 18 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.